Skip to Content

Icon PLC

ICLR: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$124.00MhhsdxWrnpbdhx

ICON Earnings: Strong Demand for Outsourced Clinical Trials; Focus on Innovative Data Solutions

Narrow-moat Icon reported strong first-quarter results highlighted by revenue exceeding $2 billion, representing a nearly 6% increase from the prior-year period, thanks to stabilizing demand within the biotech customer base. We continue to have a positive outlook for Icon, and we maintain our fair value estimate of $268 per share. However, we view the stock as currently trading at a 12% premium to our fair value estimate.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of ICLR so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center